Christopher Anderson
Primary Care · Groton, CTNPI 1669889820
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 319 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 31.2% of the total. Reporting peaked in 2023 at $1,329 and has fallen 61.2% since, to $516 in 2025. Among primary care clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 319 payments — averaging $14.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$923
- Corium, LLC$404
- Phathom Pharmaceuticals, Inc.$396
- Supernus Pharmaceuticals, Inc.$322
- AstraZeneca$158
- plus $912 from 19 others
What the payments were for
- Food & beverage$4,41397%
- Education$1163%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$116
How this compares
$4,529 in reported general payments places this provider in the 95th percentile of 111 primary care providers in Connecticut.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $29,492 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $14,545 |
| XanaxAlprazolam | 11 | $9,944 |
| Butalbital-Acetaminophen-CaffeButalb/Acetaminophen/Caffeine | 16 | $2,500 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 23 | $2,389 |
| Oxycodone Hcl | 37 | $814 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 40 | $755 |
| Methadone Hcl | 13 | $691 |
| Hydromorphone Hcl | 14 | $603 |
| Gabapentin | 31 | $490 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 21 | $461 |
| Alprazolam | 49 | $286 |
| Tramadol Hcl | 14 | $243 |
| Lorazepam | 39 | $232 |
| Omeprazole | 11 | $201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $923 | $29,49231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 111 primary care providers in Connecticut.
Other primary care in Groton
- Kelly NolinEnfield$16K
- Deanna BallardDanbury$7K
- Jacqueline VelezBridgeport$7K
- Joyce WallHamden$5K
- Catherine KrenickyPawcatuck$5K
- Carolyn BrownMiddlebury$4K
- Ivanna TsykhulyakWaterbury$3K
- Rosaleen GalvinBridgeport$3K
- Erica SeebeckWilton$3K
- Muhammad ZubairiEast Hartford$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.